Oligomerix, Inc., a privately held clinical stage company pioneering the development of oral, small molecule therapeutics ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
Today, educational software company Dynamoid announced the launch of the 10k Science immersive 3D experience collection. Among numerous updates to the main 10k Science VR application, including major ...
RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal ...
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in ...
WHITE RIVER JUNCTION, Vt., Nov. 18, 2025 /PRNewswire/ -- QUEL Imaging, a leader in biomedical optical characterization tools and services, and the Institut National d'Optique (INO), Canada's premier ...
FYR Bio ("FYR"), a leader in liquid-biopsy precision medicine for neuro-oncology, today announced a collaboration with NuvOx Therapeutics, Inc. ("NuvOx") supported by a two-year $1,976,897 ...
Dear Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties : As we prepare to end 2025, we would like to provide you with this open letter summarizing our ...
March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Among the large, international biotechnology companies in the exhibit hall at ASN Kidney Week was at least one startup ...
On November 13, 2025, effective November 14, 2025 the Securities and Exchange Commission (“Commission”), in Administrative Proceeding File No. 3-22541, in Release No. 104178 issued an Order Making ...
The record-setting government shutdown was just the latest blow to the U.S. biopharma industry. When science funding becomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback